-
2025-522932-15-00
3
Systemic Lupus Erythematosus
-
2025-523005-15-00
9
Non-Hodgkin Lymphoma
-
2025-523425-17-00
4
Proteinuric kidney diseases
-
2025-523443-35-00
5
Persistent Corneal Epithelial Defect (PCED)
-
2025-523750-14-00
5
refractory hypotension in distributive shock
-
2025-523828-51-00
5
CACNA1A Disorders
-
2025-523845-90-00
3
Relapsed/Refractory Hematologic Autoimmune Disease
-
2025-523869-22-00
5
advanced or metastatic extrapulmonary neuroendocrine carcinoma
-
2025-523947-36-00
4
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherap
-
2025-524386-24-00
5
Head and neck cancer
-
2025-524443-12-00
4
Post Covid Syndrome (PCS)
-
2025-524468-40-00
3
chronic Graft-versus-Host-Disease (cGvHD)
-
2026-525640-14-00
6
Candidemia
-
2025-523567-38-00
4
2026-06-02
locally advanced or metastatic NSCLC
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2025-522255-25-00
5
2026-05-18
Fallopian Tube Neoplasms
-
2025-520452-28-00
4
2026-05-12
Recurrent urinary tract infections (rUTI)
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-519830-22-00
5
2026-04-27
Heart failure due to systemic left ventricular systolic dysfunction
-
2024-517943-29-00
5
2026-04-21
Pulmonary Hypertension associated with interstitial lung disease (WHO
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2024-519578-38-00
10
2026-03-30
Classic congenital adrenal hyperplasia
-
2025-522402-21-00
1
2026-03-27
Advanced solid tumors (cutaneous melanoma, mucosal melanoma, cutaneous
-
2025-523533-25-00
10
2026-03-26
Cancer-associated Cachexia